From Embolic Stroke of Undetermined Source (ESUS) to Patent Foramen Ovale-Associated Stroke: Diagnosis and Reclassification
Cureus · 10.11.2026
DOI: 10.7759/cureus.119417 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cureus, erschienen am 10.11.2026. Verfasst von David Martinez Juarez und 2 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben.
Themen: Schlaganfall
Abstract (Originalsprache)
Embolic stroke of undetermined source (ESUS) represents a heterogeneous clinical entity encompassing multiple potential embolic mechanisms that may remain unidentified after a standard diagnostic evaluation.This heterogeneity poses significant challenges for therapeutic decision-making, particularly regarding anticoagulation strategies and targeted interventions.In recent years, structured phenotyping systems such as the Ischemic Stroke Phenotyping System 2025 (ISPS25), together with probabilistic tools including the Risk of Paradoxical Embolism (RoPE) score and the PFO-associated Stroke Causal Likelihood (PASCAL) classification, have been proposed to refine etiological attribution in patients with ESUS.We report the case of a 40-year-old woman who presented with sudden-onset vertigo, nausea, and vomiting.Brain magnetic resonance imaging (MRI) demonstrated an ischemic stroke with an embolic pattern.Initial vascular, cardiac, and laboratory evaluations failed to identify a definitive cause, fulfilling the diagnostic criteria for ESUS.A comprehensive diagnostic approach, including transthoracic echocardiography (TTE) and cardiac magnetic resonance (CMR), revealed a patent foramen ovale (PFO) with high-risk anatomical features, specifically an atrial septal aneurysm (ASA), in the absence of other identifiable cardioembolic sources.Application of the ISPS25 enabled a structured etiological reassessment, while integration of the RoPE score and the PASCAL classification supported a high likelihood of a PFO-related ischemic stroke.Structured etiological phenotyping, complemented by probabilistic tools such as ISPS25, RoPE, and PASCAL, may enhance diagnostic precision in ESUS and guide individualized therapeutic decision-making.In this case, such an approach provided a coherent diagnostic pathway that supported percutaneous PFO closure as a targeted strategy for secondary stroke prevention.
Zitieren
APA
Juarez, D. M., Gomez-Monterrosas, O., & Ortiz-Chávez, M. A. (2026). From Embolic Stroke of Undetermined Source (ESUS) to Patent Foramen Ovale-Associated Stroke: Diagnosis and Reclassification. Cureus. https://doi.org/10.7759/cureus.119417
Vancouver
Juarez DM, Gomez-Monterrosas O, Ortiz-Chávez MA. From Embolic Stroke of Undetermined Source (ESUS) to Patent Foramen Ovale-Associated Stroke: Diagnosis and Reclassification. Cureus. 2026. doi:10.7759/cureus.119417
BibTeX
@article{Juarez2026,
author = {Juarez, David Martinez and Gomez-Monterrosas, Omar and Ortiz-Chávez, Marco Antonio},
title = {From Embolic Stroke of Undetermined Source (ESUS) to Patent Foramen Ovale-Associated Stroke: Diagnosis and Reclassification},
journal = {Cureus},
year = {2026},
doi = {10.7759/cureus.119417}
}
EUVIMED